THE EFFECTIVENESS OF BACILLUS CALMETTE-GUERIN (BCG) VACCINATION AGAINST TUBERCULOSIS

Abstract

Bacillus Calmette-Guérin (BCG) vaccination against tuberculosis has been used around the world for 60 years, yet its efficacy in large, controlled prospective studies is inconsistent. The factors influencing BCG protection include variation in immunogenic potential, background exposure to environmental mycobactena, and differences in host response to vaccine. As a means of addressing regional differences in protection, case-control studies provide a relatively inexpensive, rapid means of assessing regional vaccine effects. Treaty Indian cases (n = 160) resident in Alberta, Canada, presenting during a 5-year period (1975–1979) were individually matched for age, sex, and Band with two nontuberculous controls. A 57 percent protection by BCG vaccination was demonstrated. These results support the usefulness of case-control studies and their importance in planning tuberculosis control programs.